Lab Services

Praava's laboratory is one the most sophisticated setups in Bangladesh. Accurate laboratory diagnostics are essential to your good health. These might include blood tests, tests requiring samples of your urine or stool, and other services such as Pap tests and biopsies. Lab testing may be part of a routine check-up, help your doctor make a diagnosis, or be necessary for monitoring health conditions. If you have a chronic condition such as high cholesterol or diabetes, your doctor may ask you to come in regularly for tests to monitor your health. You may also request certain services yourself, such as screening for sexually transmitted infections.

Praava's full range of on-site lab services include the following laboratories:
  • Biochemistry & Immunochemistry
  • Microbiology & Serology
  • Hematology & Coagulation
  • Histopathology & Cytopathology
  • Immunohistochemistry
  • Clinical Pathology
  • Molecular Cancer Diagnostics

In addition, we offer Home Sample Collection including blood and urine samples. The integrity of our laboratory is essential to quality services we offer at Praava. We can assure you that our test results are at par with international standard laboratories.

Molecular Cancer Diagnostics

Our state of the art laboratory features Bangladesh's first Molecular Cancer Diagnostics (PCR) laboratory.

Globally, cancer now causes more deaths than HIV/AIDS, tuberculosis, and malaria combined. Cancer, including colorectal, breast, cervical, and lung cancer, is now a threat to the population of Bangladesh. Diagnosis of these diseases will serve both preventative and therapeutic benefits.

Oncology molecular diagnostics, including for colorectal, breast, cervical and lung cancers, has been most effective and can reduce cancer mortality based on early detection as well as disease management. Also, rapid turnaround times are crucial when making decisions regarding targeted therapies for cancer Patients.

Praava's Cancer Diagnostic Tests

Praava's Molecular Cancer Diagnostics lab has a state of the art facility for screening and diagnosis of cancer in Bangladesh. We are focused on early detection of colorectal, breast, cervical, and lung cancers to allow for their appropriate diagnosis and treatment.

    • KRAS Seven Mutations Detection profile is a sensitive and selective assay for the detection of the most common somatic mutations in the KRAS gene. This test amplifies exon 2 of K-RAS gene associated with colorectal cancer and its precursor lesions. Mutations in KRAS codons 12 and 13 have been associated with lack of response to EGFR-targeted therapies in CRC Patients (>93%). Absence of mutation predicts greater sensitivity to EGFR-targeted therapies and improved survival.
    • KRAS mutation detection to guide anti-EGFR therapy
    • Fecal occult blood/FIT, Septin 9 gene methylation by PCR
    • This test amplifies HER2 gene, predicting responsiveness to trastuzumab therapy. Positive result (amplification of HER2) predicts responsiveness to trastuzumab therapy. Samples negative and positive for HER2 overamplification can readily be discriminated. The results achieved are unambiguous and comparable between runs and individual samples. This real-time quantitative PCR test offers a rapid detection method for HER2 DNA overamplification in breast tissue samples.
    • HER2 gene amplification to confirm IHC/FISH results performed elsewhere.
    • Mammography, HER2 gene amplification test, ER/PR test.
    • Human papillomavirus (HPV) is a sexually transmitted DNA virus that establishes infection in squamous epithelial cells in the human body. High-risk HPV infection is necessary for the development of cancers of the uterine cervix, which has been firmly established. Approximately 99.7% of cervical cancers are caused by high-risk HPV infection. In particular, HPV16 and HPV18 are known to cause around 70% of cervical cancer cases.
    • HPV16/18 genotyping.
    • HPV16/18 genotyping, PAP test, CT, MRI.
    • For Patients who may receive anti-EGFR monoclonal antibodies (e.g. cetuximab, panitumumab) or tyrosine kinase inhibitors (e.g. erlotinib).
    • This test amplifies deletion in exon 19 and / or a mutation in exon 21 (L858R), EGFR gene associated with non-small cell lung cancer (NSCLC) and its precursor lesions. Mutations in EGFR have been associated with lack of response to EGFR-targeted therapies in NSCLC Patients (>93%). Absence of mutation predicts greater sensitivity to EGFR targeted therapies and improved survival. Vast majority of Patients receiving TKI therapy will develop resistance and may acquire exon 20 T790M mutation. Since inhibitors against this mutation are available, we will also test for EGFR T790M mutation in a separate assay.
    • EGFR.
    • ALK.
    • ROS1.
    • BRAF.
    • Mutation detection.
    • EGFR; ALK; ROS1; BRAF.
    • Septin 9 liquid biopsy is a molecular test that detects methylated Septin 9 DNA in blood. DNA methylation of the Septin 9 gene is increased in colorectal cancer. Methylated Septin 9 DNA can be found in tumor DNA that has been shed and this plasma-based test requires no patient preparation. The test may be ordered for screen-eligible Patients who have avoided routine colorectal cancer screening methods such as colonoscopy, fecal occult blood tests, and fecal immunochemical tests (FITs). The test uses polymerase chain reaction (PCR) for the methylation specific detection of the Septin 9 DNA target. The Septin 9 test results, together with the physician's assessment of history, other risk factors, and professional guidelines, may be used to guide patient management. Patients with a positive test result should be referred for diagnostic colonoscopy.
    • Tumor Profile-Female (TPF)
      • AFP, CEA, CA 15.3, CA 19.9, CA 125, b-HCG
    • Tumor Profile-Male (TPF)
      • PSA, Free-PSA, AFP, CEA, CA 19.9, b-HCG
Praava also offers other diagnostics targeting BRAF, EGFR, EML4-ALK, ROS1 and has introduced non-invasive, lower cost, blood-based testing (liquid biopsy) of Septin 9 methylated DNA to detect colon cancer.

Diagnostics Planning For What's Next

Praava Health will continue to follow the latest news and technologies and bring the highest quality treatment options to our Patients. We are committed to using the latest diagnostic technology for early detection and treatment of cancer, including quantitation of circulating tumor cells as a future offering.